Table 1.
Author | Country | Type of study | Sample size (male/female) | Mean Age | Number of patients with liver toxicity | CRP (mg/l) | Serum levels (ALT: U/L, AST: U/L, Bilirubin: mg/dL, Albumin: g/L) | LDH (U/L) | D-dimer (μg/mL) | ESR (mm/h) | Diagnosis method | Clinical stage of liver enzymes data | Q/A score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Huang et al.2 | China | C/S | 41 (30/11) | 49.0 (41.0-58.0) | - | - | ALT: 32.0 (21.0-50.0) | 286.0 (242.0-408.0) | 0.5 (0.3-1.3) | - | RT-PCR | On admission | 8 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: 31.4 (28.9-36.0) | |||||||||||||
Guan et al.23 | China | C/S | 1,099 (637/459) | 47.0 (35.0-58.0) | - | - | ALT: - | - | - | - | RT-PCR | On admission | 8 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Fu et al.24 | China | C/S | 52 (28/24) | 44.5 (33.0-56.5) | 10 | 8.8 (3.5-21.4) | ALT: 24.0 (15.3-39.0) | 224.0 (200.0-253.0) | 0.7 (0.5-0.8) | - | RT-PCR | On admission | 7 |
AST: 27.0 (21.2-34.0) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Zhou et al.25 | China | C/S | 191 (119/72) | 56.0 (46.0-67.0) | - | - | ALT: 30.0 (17.0-46.0) | 300.0 (234.0-407.0) | 0.8 (0.4-3.2) | - | RT-PCR | On admission | 8 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: 32.3 (29.1-35.8) | |||||||||||||
Chen et al.26 | China | Case series | 9 (0/9) | 29.9 | - | 18.61 | ALT: 253.8 | - | - | - | RT-PCR | On admission | 5 |
AST: 171.0 | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Chen et al.27 | China | C/S | 291 (145/146) | 46.0 (34.0-59.0) | - | 15.6 (4.4-30.3) | ALT: 20.7 (14.9-28.9) | 172.8 (142.6-220.5) | - | 37.0 (21.0-62.0) | RT-PCR | On admission | 8 |
AST: 24.7 (19.9-31.4) | |||||||||||||
Bilirubin: 27.0 | |||||||||||||
Albumin: 37.3 (34.7-40.3) | |||||||||||||
Chen et al.28 | China | C/S | 274 (171/103) | 62.0 (44.0-70.0) | 13 | 53.4 (18.6-113.0) | ALT: 23.0 (15.0-38.0) | 321.5 (249.8-510.5) | 1.1 (0.5-3.2) | 32.5 (17.3-53.8) | RT-PCR | On admission | 8 |
AST: 30.0 (22.0-46.0) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: 33.9 (30.3-37.6) | |||||||||||||
Chen et al.29 | China | C/S | 99 (67/32) | 55.5 (21.0-82.0) | - | 51.4 | ALT: 39.0 (22.0-53.0) | 336.0 (260.0-447.0) | 0.9 (0.5-2.8) | 49.9 | RT-PCR | On admission | 8 |
AST: 34.0 (26.0-48.0) | |||||||||||||
Bilirubin: 15.1 | |||||||||||||
Albumin: 31.6 | |||||||||||||
Ai et al.30 | China | C/S | 102 (52/50) | 50.4 (1.5-90.0) | - | 28.2 | ALT: 27.8 | 245.4 | - | 33.3 | RT-PCR and CT-scan | On admission | 8 |
AST: 30.6 | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Xu et al.31 | China | C/S | 355 (162/193) | - | - | ALT: 35.0 (1.0-414.0) | 296.4 | 2.7 (0.1-382.0) | - | RT-PCR | On admission | 8 | |
AST: 40.76 (10.0-475.0) | |||||||||||||
Bilirubin: 14.16 (0.7-511.6) | |||||||||||||
Albumin: 38.5 (18.2-56.1) | |||||||||||||
Zhang et al.32 | China | C/S | 95 (42/53) | 49.0 (39.0-58.0) | 50 | 25.0 | ALT: - | - | - | - | RT-PCR and abnormal radiologic findings | During admission | 8 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Zhao et al.5 | China | C/S | 75 (33/42) | 47.0 (34.0-55.0) | - | 13.6 (3.8-48.2) | ALT: 23.0 (14.0-43.0) | 233.0 (176.5-313.0) | - | 30.1 (11.5-69.0) | RT-PCR | On admission | 7 |
AST: 27.0 (21.0-37.0) | |||||||||||||
Bilirubin: 14.5 (11.1-18.2) | |||||||||||||
Albumin: - | |||||||||||||
Zhao et al.33 | China | C/S | 77 (34/43) | 52.0 | 25 | 17.0 (4.6-51.1) | ALT: 28.0 (20.0-46.0) | - | - | - | RT-PCR | On admission | 8 |
AST: 29.0 (21.0-42.0) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Tian et al.34 | China | C/S | 37 (17/20) | 44.3 | - | ALT: - | - | - | - | RT-PCR | During admission | 7 | |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Wang et al.35 | China | C/S | 339 (166/173) | 71.0 | 96 | 49.6 (18.5-93.2) | ALT: 27.0 (17.0-44.0) | 301.0 (224.0-429.0) | 1.2 (0.6-3.2) | - | RT-PCR | On admission | 8 |
AST: 32.0 (23.0-46.0) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Wang et al.36 | China | C/S | 11 (10/1) | 58.0 (49.0-72.0) | 6 | 12.1 (6.2-13.7) | ALT: 24.0 (15.9-27.7) | 396.5 (357.6-529.0) | 1.3 (6.7-4.7) | - | RT-PCR | During admission | 6 |
AST: - | |||||||||||||
Bilirubin: 15.1 (11.2-20.4) | |||||||||||||
Albumin: 33.6 (30.5-37.2) | |||||||||||||
Huang et al.37 | China | C/S | 36 (25/11) | 69.2 | 22 | 106.2 (60.8-225.3) | ALT: 26.0 (18.0-38.0) | 502.5 (410.0-629.0) | 8.6 (2.4-20.0) | - | RT-PCR | On admission | 5 |
AST: 43.0 (30.0-51.0) | |||||||||||||
Bilirubin: 11.2 (7.5-19.2) | |||||||||||||
Albumin: 30.2 | |||||||||||||
Zhang et al.38 | China | C/S | 82 (54/28) | 72.5 | 64 | 11.7 (63.3-186.6) | ALT: 26.0 (18.5-47.5) | 515.0 (365.0-755.0) | 5.1 (2.2-21.5) | - | RT-PCR | During admission | 6 |
AST: 72.0 (30.0-71.0) | |||||||||||||
Bilirubin: 13.6 (10.0-22.9) | |||||||||||||
Albumin: 33.1 (30.3-36.9) | |||||||||||||
Zhang et al.39 | China | C/S | 140 (71/69) | 57.0 | - | 34.2 (12.5-67.4) | ALT: - | - | 0.2 (0.1-0.5) | - | RT-PCR | During admission | 8 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Zhang et al.40 | China | C/S | 28 (17/11) | 65.0 | - | - | ALT: - | 262.9 (168.5-508.0) | - | - | RT-PCR | Medical records, NA | 6 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: 31.1 (28.6-34.8) | |||||||||||||
Zhao et al.41 | China | C/S | 34 (11/8) | 48.0 | - | 26.5 (10.0-127.1) | ALT: 36.4 (11.8-85.0) | 256.9 (150.0-750.0) | - | - | RT-PCR | After admission | 7 |
AST: 34.9 (17.6-103.8) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Tang et al.42 | China | C/S | 73 (45/28) | 67.0 | 33 | 87.2 (32.6-104.5) | ALT: 34.5 (24.0-61.0) | 483.0 (351.0-602.0) | 0.6 (0.4-3.4) | - | Clinical presentations, CT-scan | On admission | 7 |
AST: 25.5 (20.0-42.5) | |||||||||||||
Bilirubin: 9.8 (8.0-14.5) | |||||||||||||
Albumin: 33.2 (30.8-36.2) | |||||||||||||
Tang et al.43 | China | C/S | 26 (17/9) | 6.9 | - | - | ALT: - | - | - | - | RT-PCR | Medical records, NA | 6 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Liao et al.44 | China | C/S | 46 (24/22) | - | - | 2.6 (0.8-9.4) | ALT: 17.9 (11.6-32.5) | 195.5 (145.0-240.0) | 0.3 (0.2- 0.4) | - | RT-PCR assay with a cycle threshold value (Ct-value) of less than 37 was defined as positive | On admission | 8 |
AST: 18.3 (14.5-26.9) | |||||||||||||
Bilirubin: 8.7 (5.9-14.6) | |||||||||||||
Albumin: - | |||||||||||||
Qian et al.45 | China | C/S | 91 (37/54) | 50.0 (36.5-57.0) | - | 6.8 (1.9-15.3) | ALT: 18.0 (13.0-28.0) | - | 0.3 (0.1-0.4) | - | Real-time reverse transcriptase as a primary method of diagnosis, RT-PCR | On admission | 9 |
AST: 21.0 (17.0-28.0) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: 40.0 (37.8-42.0) | |||||||||||||
Qiu et al.46 | China | C/S | 104 (49/55) | 43.0 | 5 | 11.7 (3.5-32.7) | ALT: 20.0 (15.0-34.2) | - | 0.5 (0.2-0.7) | - | RT-PCR | NA | 9 |
AST: 26.0 (20.8-34.1) | |||||||||||||
Bilirubin: 10.9 (7.5-16.6) | |||||||||||||
Albumin: 37.3 | |||||||||||||
Shi et al.47 | China | C/S | 101 (60/41) | - | 18 | 107.9 | ALT: 56.0 | - | - | - | NA (Medical records) | On admission | 7 |
AST: 116.8 | |||||||||||||
Bilirubin: 25.0 | |||||||||||||
Albumin: - | |||||||||||||
Wan et al.48 | China | C/S | 135 (72/63) | 47.0 (36.0-55.0) | - | 10.5 (2.7-51.2) | ALT: 26.0 (12.9-33.1) | 320.5 (248.5-385.3) | 0.4 (0.2-0.6) | - | RT-PCR | Medical records, NA | 8 |
AST: 33.4 (27.8-43.7) | |||||||||||||
Bilirubin: 8.6 (5.9-13.7) | |||||||||||||
Albumin: 40.5 (37-43.4) | |||||||||||||
Xu et al.49 | China | C/S | 55 (22/33) | 49.0 (2.0-69.0) | - | - | ALT: - | - | - | - | RT-PCR | Pathology sample from the liver after death | 5 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Wu et al.50 | China | C/S | 80 (39/41) | 46.1 | 3 | 6.6 (5.3-12.3) | ALT: 24.0 (12.0-38.0) | 226.0 (182.0-308.0) | 0.9 (0.4-2.4) | Epidemiological history, clinical manifestations, RT-PCR | Medical records, NA | 8 | |
AST: 30.0 (19.0-39.0) | |||||||||||||
Bilirubin: 6.6 (5.4-12.0) | |||||||||||||
Albumin: 38.3 (37.0-46.2) | |||||||||||||
Xie et al.51 | China | C/S | 79 (44/35) | 60.0 (48.0-66.0) | 29 | 13.9 (3.1-51.9) | ALT: 34.0 (18.0-67.0) | - | 0.7 (0.3-1.3) | 39.0 (24.0-58.0) | RT-PCR, clinical data | On admission | 8 |
AST: 30.0 (23.0-50.0) | |||||||||||||
Bilirubin: 13.6 (8.8-17.6) | |||||||||||||
Albumin: - | |||||||||||||
Xu et al.52 | China | C/S | 45 (29/16) | 56.7 | 17 | ALT: 29.0 (20.1-50.0) | 338.0 (248.0-437.9) | - | - | All patients had positive throat swabs of SARS-CoV-2 | On admission | 8 | |
AST: 27 (22.0-39.5) | |||||||||||||
Bilirubin: 15.5 (10.5-21.3) | |||||||||||||
Albumin: 31.6 (30.2-34.5) | |||||||||||||
Zhou et al.25 | China | C/S | 191 (119/72) | 56.0 (46.0-67.0) | - | ALT: 30.0 (17.0-46.0) | 300.0 (234.0-407.0) | 0.8 (0.4-3.2) | - | Real-time RT-PCR methods | On admission | 7 | |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: 32.3 (29.1-35.8) | |||||||||||||
Zhou et al.53 | China | C/S | 197 (99/98) | 55.9 | 8 | 55.0 | ALT: 38.4 | 266.2 | 2.3 | - | RT-PCR, CT-scan | On admission | 7 |
AST: 38.8 | |||||||||||||
Bilirubin: 16.3 | |||||||||||||
Albumin: - | |||||||||||||
Cai et al.54 | China | C/S | 417 (198/219) | 47.0 (34.0-60.0) | 22 | ALT: 21.0 (15.0-31.0) | - | - | - | RT-PCR | On admission | 8 | |
AST: 26.5 (21.0-35.0) | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Feng et al.17 | China | C/S | 476 (271/205) | 53.0 (40.0-64.0) | - | 18.8 (5.2-57.0) | ALT: - | 259.0 (202.0-356.0) | 0.58 (0.35-1.48) | 48.0 (30.0-80.0) | Real-time RT-PCR, CT-scan | On admission | 8 |
AST: - | |||||||||||||
Bilirubin: 10.1 (7.5-14.0) | |||||||||||||
Albumin: 37.9 (32.8-41.8) | |||||||||||||
Feng et al.55 | China | C/S | 564 (284/280) | 47.0 (36.0-58.0) | - | ALT: 20.3 (15.0-30.4) | 189.0 (152.0-244.0) | - | - | RT-PCR assay for nasal and pharyngeal swab specimens, CT-scan | On admission | 8 | |
AST: 24.3 (19.5-31.5) | |||||||||||||
Bilirubin: 11.9 (8.7-17.6) | |||||||||||||
Albumin: 39.0 (35.7-42.4) | |||||||||||||
Fu et al.18 | China | C/S | 50 (27/23) | - | - | - | ALT: - | - | - | - | RT-PCR, CT-scan | NA | 8 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Ji et al.56 | China | C/S | 208 (117/91) | 44.0 | - | ALT: 24.0 (14.0-37.3) | 234.0 (200.0-283.0) | 0.3 (0.2-0.5) | - | RT-PCR | On admission | 8 | |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Han et al.57 | China | C/S | 25 (12/13) | 44.0 (22.0-70.0) | - | - | ALT: - | - | - | - | NA | On admission | 7 |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - | |||||||||||||
Jiang et al.58 | China | C/S | 55 (27/28) | 45.0 (27.0-60.0) | - | 8.8 (3.5-21.4) | ALT: 21.0 (16.0-48.0) | - | 0.3 (0.2-0.6) | - | RT-PCR | Medical records, NA | 7 |
AST: 24.0 (20.0-32.0) | |||||||||||||
Bilirubin: 7.0 (4.0-10.0) | |||||||||||||
Albumin: 42.0 (39.0-45.0) | |||||||||||||
Yang et al.59 | China | C/S | 92 | - | 15 | 15.6 (4.4-30.3) | ALT: - | - | - | RT-PCR | Medical records, NA | 8 | |
AST: - | |||||||||||||
Bilirubin: - | |||||||||||||
Albumin: - |
CRP: C-reactive protein, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, LDH: Lactate dehydrogenase, ESR: Erythrocyte sedimentation rate, Q/A: Quality assessment, RT-PCR: Reverse transcription polymerase chain reaction, CT-scan: Computed tomography scan, C/S: Cross-sectional